Page 14 - Dr Reddy's Laboratories
Dr Reddy's Q3 net profit dips by 19% to Rs 470 cr
Revenues dropped by 7% to Rs 3,707 crore y-o-y
 "Dr Reddy's Q3 net profit dips by 19% to Rs 470 cr")
USFDA to re-inspect Dr Reddy's plants by March
The company received a warning letter from the USFDA on November 5, 2015, for specific violations
 "USFDA to re-inspect Dr Reddy's plants by March")
Dr Reddys Lab hits three-month high
In past three-trading sessions, post QFY17 results the stock gained 7% as compared to 1.62% decline in Sensex
 "Dr Reddys Lab hits three-month high")
Dr Reddy's announces collaboration with Gland Pharma for US market
Combined sale of branded and generic versions of the products in the US is approximately $1 billion
 "Dr Reddy's announces collaboration with Gland Pharma for US market")
Dr Reddy's Q2 net down 60% at Rs 308 cr as US generic sales plunge
Declining US sales had a bearing on the company's revenues and profitability
 "Dr Reddy's Q2 net down 60% at Rs 308 cr as US generic sales plunge")
Poor sales in North America plunge Dr Reddy's Q2 profit; down 60% to Rs 31 cr
Shares of DRL were trading at Rs 3,115.60 on BSE during the morning trading hour, up 0.84 per cent from previous close
Dr Reddy's launches anti-epileptic medicine in the US market
The product is a generic equivalent of Lamictal ODT in the US; Lamictal ODT is a registered trademark of GSK group
 "Dr Reddy's launches anti-epileptic medicine in the US market")
Is Dr Reddy's Lab out of the woods?
Faster pace of product launches can drive recovery in growth, but for regulatory clearances
Dr Reddy's to market three more Amgen products in India
The drugs provide treatment options to physicians to address unmet medical needs in the area of oncology and osteoporosis
Dr Reddy's listed on Dow Jones Sustainability Indices 2016
The Dow Jones Sustainability Indices is a leading global benchmark for corporate sustainability
A prescription for success: Dr Reddy's makes pharma packaging more patient-friendly
Redesigns its syrup bottles and blister packs
 "A prescription for success: Dr Reddy's makes pharma packaging more patient-friendly")
Dr Reddy's completes acquisition of Teva's US portfolio of 8 products
Pharma major expects some products to add to its topline in 2018; products were being divested by Teva as a condition to close acquisition with Allergan
Company will emerge more stronger and resilient: Dr Reddy's chairman
The company on Tuesday revealed that it was in the process of writing to the USFDA for re-inspection of the three manufacturing sites
Can Dr Reddy's overcome the steep challenges it faces?
Despite assurances, the Indian generics drug major has failed to show any hint of turnaround, however small, from any segment or geography
Dr Reddy's Q1 net down 80% at Rs 126 crore
Pharma major's bottomlines impacted by a decline in volume growth, particularly in the US market and the loss of business in Venezuela
Dr Reddy's Labs Q1 profit slumps 75%
Net profit for the April-June quarter fell to Rs 154 crore from Rs 626 crore the previous year,
 "Dr Reddy's Labs Q1 profit slumps 75%")
Dr Reddy's launches anti-ulcer capsules in US
Drug is generic equivalent of Zegerid capsules, which has a market of $307 million in twelve months to May 2016
 "Dr Reddy's launches anti-ulcer capsules in US")
Dr Reddy's to have stronger quality system by 2016-end: G V Prasad
This follows firm's remediation efforts after USFDA's warning letter over certain compliance issues last year
 "Dr Reddy's to have stronger quality system by 2016-end: G V Prasad")
Dr Reddy's Lab completes share buyback; stock hit seven-month high
The stock outperformed the market by surging 10% as compared to 0.17% rise in Sensex during past eight trading sessions.
 "Dr Reddy's Lab completes share buyback; stock hit seven-month high")
Multiple headwinds for Dr Reddy's in FY17
Price erosion in the US and higher R&D costs are major concerns